Immunogenicity of Factor VIII (FVIII) is a major hurdle that affects about 30% of severe hemophilia A patients. Though a significant advancement has been accomplished in the development of newer FVIII molecules, the factors that drive FVIII immune responses remain elusive. Many genetic and environmental risk factors have been identified or suggested but a complete understanding of the immunological basis for the antibody formation and the mechanism(s) behind tolerance induction, in the 30% of the patients that never develop anti-FVIII antibodies, are not understood. My thesis involves overlapping aspects important for initiation of an anti-FVIII immune response in a mouse model of hemophilia A. The primary role of FVIII is its participation...
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to prolon...
Introduction Inhibitor formation against coagulation factor VIII (FVIII) is an unresolved serious p...
The development of neutralizing antibodies against factor VIII (FVIII), so called ‘inhibitors’, is o...
Immunogenicity of Factor VIII (FVIII) is a major hurdle that affects about 30% of severe hemophilia ...
Immunogenicity of Factor VIII (FVIII) is a major hurdle that affects about 30% of severe hemophilia ...
L’apparition d’une réponse immunitaire contre le Facteur VIII (FVIII) de la coagulation est une comp...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
La survenue d'anticorps neutralisant le facteur VIII de la coagulation (FVIII) chez les patients hém...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to prolon...
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to prolon...
Introduction Inhibitor formation against coagulation factor VIII (FVIII) is an unresolved serious p...
The development of neutralizing antibodies against factor VIII (FVIII), so called ‘inhibitors’, is o...
Immunogenicity of Factor VIII (FVIII) is a major hurdle that affects about 30% of severe hemophilia ...
Immunogenicity of Factor VIII (FVIII) is a major hurdle that affects about 30% of severe hemophilia ...
L’apparition d’une réponse immunitaire contre le Facteur VIII (FVIII) de la coagulation est une comp...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
Occurrence of pro-coagulant factor VIII (FVIII) neutralizing antibodies in hemophilia A patients con...
La survenue d'anticorps neutralisant le facteur VIII de la coagulation (FVIII) chez les patients hém...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
Hemophilia A (HA) is a rare congenital hemorrhagic disorder resulting from a defective production of...
Hemophilia A is an X chromosome-linked bleeding disorder caused by a reduction or complete absence ...
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to prolon...
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to prolon...
Introduction Inhibitor formation against coagulation factor VIII (FVIII) is an unresolved serious p...
The development of neutralizing antibodies against factor VIII (FVIII), so called ‘inhibitors’, is o...